menu
    • menu
    [{"orgOrder":0,"company":"Syneos Health","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","graph1":"Oncology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Syneos Health \/ Daiichi Sankyo","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Syneos Health","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Daridorexant","moa":"OX1R\/OX2R","graph1":"Sleep","graph2":"Approved","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"12","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Byondis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Trastuzumab duocarmazine","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Revance Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Daxibotulinumtoxin A","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Idorsia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Daridorexant","moa":"OX1R\/OX2R","graph1":"Sleep","graph2":"Approved","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Film-Coated Tablet","sponsorNew":"Syneos Health \/ Idorsia Ltd","highestDevelopmentStatusID":"12","companyTruncated":"Syneos Health \/ Idorsia Ltd"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Revance Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Daxibotulinumtoxin A","moa":"Ach","graph1":"Neurology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Cryoport Systems Inc","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"3","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Creative Medical Technology","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"CELZ-201","moa":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Syneos Health \/ Creative Medical Technology","highestDevelopmentStatusID":"7","companyTruncated":"Syneos Health \/ Creative Medical Technology"},{"orgOrder":0,"company":"Syneos Health","sponsor":"FivepHusion","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Fluorouracil","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"7","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"The Italfarmaco Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Givinostat","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Crossject","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Midazolam","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Syneos Health \/ Crossject","highestDevelopmentStatusID":"12","companyTruncated":"Syneos Health \/ Crossject"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Odyssey Health","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"ONP-002","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Syneos Health \/ Odyssey Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Odyssey Health"}]

    Find Clinical Drug Pipeline Developments & Deals by Syneos Health

    Menu

    Syneos Health

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Syneos Health

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Syneos Health

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Midazolam

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Crossject

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE®

                            Details : Under the agreement, Syneos Health will provide support in all pre-launch and launch activities for Zepizure (midazolam), an epileptic rescue therapy for epileptic seizures.

                            Brand Name : Zepizure

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 04, 2024

                            Lead Product(s) : Midazolam

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Crossject

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Syneos Health

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Syneos Health

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ONP-002

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase I

                            Sponsor : Odyssey Health

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Odyssey Health, Inc, Selects Syneos Health to Support Investigational New Drug Application for Treatment of Co...

                            Details : ONP-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of moderate traumatic brain injury. It crosses BBB & activates gene response leading to the production of proteins that reduce inflammation, oxidative str...

                            Brand Name : PRV-002

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 16, 2023

                            Lead Product(s) : ONP-002

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase I

                            Sponsor : Odyssey Health

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Syneos Health

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Syneos Health

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Givinostat

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Recipient : The Italfarmaco Group

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Italfarmaco Group Completes FDA Submission of New Drug Application for Givinostat in Duchenne Muscular Dystrop...

                            Details : ITF2357 (givinostat) is an investigational drug act as a inhibits histone deacetylases (HDACs), which is investigated for the treatment of Duchenne Muscular Dystrophy.

                            Brand Name : ITF2357

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 29, 2023

                            Lead Product(s) : Givinostat

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Recipient : The Italfarmaco Group

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Syneos Health

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Syneos Health

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fluorouracil,Calcium Folinate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : FivepHusion

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            FivepHusion Announces Strategic Collaboration with Treehill Partners and Syneos Health

                            Details : The collaboration is for strategically and optimally progress development and commercialization of FivepHusion's enhanced chemotherapeutic formulation Deflexifol, an anti-cancer drug reformulation combining 5-fluorouracil and its biomodulator leucovorin,...

                            Brand Name : Deflexifol

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 26, 2023

                            Lead Product(s) : Fluorouracil,Calcium Folinate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : FivepHusion

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Syneos Health

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Syneos Health

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CELZ-201

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Creative Medical Technology

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Creative Medical Technology Holdings Engages Highly Respected International CRO for Phase 1 / 2 Clinical Trial...

                            Details : CELZ-201 is the First Novel Allogenic Cellular Therapy in the Dorsal Artery of the Pancreas. CELZ-201 leverages unique approach harnessing the power of PRDC to multi-potentialities, including self-renewal ability, low antigenicity, reduced toxicity, with...

                            Brand Name : CELZ-201

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            March 07, 2023

                            Lead Product(s) : CELZ-201

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Creative Medical Technology

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Syneos Health

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Syneos Health

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Recipient : Cryoport Systems Inc

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Cryoport Announces New Strategic Partnership with Syneos Health to Advance Cell & Gene Therapies

                            Details : The partnership will support the global advancement of cell and gene therapies.The new partnership couples the full suite of clinical development services offered by Syneos Health with IntegriCell™, Cryoport's platform.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 18, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Recipient : Cryoport Systems Inc

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Syneos Health

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Syneos Health

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Daxibotulinumtoxin A

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Recipient : Revance Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Revance to Present New Clinical Data on DaxibotulinumtoxinA for Injection from the ASPEN Phase 3 Program at th...

                            Details : DaxibotulinumtoxinA for Injection, including Revance’s first oral presentation of the ASPEN-1 Phase 3 clinical trial data, the positive topline results from the ASPEN Open Label Study, which demonstrated long-term safety and efficacy of repeat treatmen...

                            Brand Name : Daxxify

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 28, 2022

                            Lead Product(s) : Daxibotulinumtoxin A

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Recipient : Revance Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Syneos Health

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Syneos Health

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Daridorexant

                            Therapeutic Area : Sleep

                            Study Phase : Approved

                            Sponsor : Idorsia Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Idorsia Expands Its Commercialization Partnership With Syneos Health for Daridorexant in Europe and Canada

                            Details : Idorsia to capitalize upon the unique opportunity to transform the insomnia treatment paradigm, notably in Europe where daridorexant would be the first dual orexin receptor antagonist made available to patients with insomnia.

                            Brand Name : Quviviq

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 26, 2022

                            Lead Product(s) : Daridorexant

                            Therapeutic Area : Sleep

                            Highest Development Status : Approved

                            Sponsor : Idorsia Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Syneos Health

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Syneos Health

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Daxibotulinumtoxin A

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Recipient : Revance Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Revance to Showcase Phase 3 Results Evaluating DaxibotulinumtoxinA for Injection for Cervical Dystonia at the ...

                            Details : Revance will present results from its ASPEN-1 Phase 3 clinical trial evaluating the efficacy and safety of DaxibotulinumtoxinA for Injection for the treatment of cervical dystonia in adults.

                            Brand Name : Daxxify

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 01, 2021

                            Lead Product(s) : Daxibotulinumtoxin A

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Recipient : Revance Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Syneos Health

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Syneos Health

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trastuzumab duocarmazine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Byondis

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Byondis Intends to Bag Commercialisation Partner for Breast Cancer ADC by 2H21

                            Details : Byondis is drafting plans to pursue commercialisation partners for when results from its Phase III breast cancer antibody-drug conjugate study are released in 2Q21.

                            Brand Name : SYD985

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 16, 2020

                            Lead Product(s) : Trastuzumab duocarmazine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Byondis

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth